Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Current Leases data on record, last reported at $981000.0 in Q3 2025.

  • For Q3 2025, Current Leases fell 50.25% year-over-year to $981000.0; the TTM value through Sep 2025 reached $981000.0, down 50.25%, while the annual FY2024 figure was $1.5 million, 32.74% down from the prior year.
  • Current Leases reached $981000.0 in Q3 2025 per AMLX's latest filing, up from $665000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $2.4 million in Q2 2024 and bottomed at $665000.0 in Q2 2025.
  • Average Current Leases over 4 years is $1.8 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Current Leases: rose 20.09% in 2023, then crashed 71.93% in 2025.
  • A 4-year view of Current Leases shows it stood at $2.0 million in 2022, then rose by 10.64% to $2.3 million in 2023, then tumbled by 32.74% to $1.5 million in 2024, then plummeted by 35.38% to $981000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $981000.0 in Q3 2025, $665000.0 in Q2 2025, and $1.1 million in Q1 2025.